Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
3
×
Tags
biotech
boston blog main
3
×
boston top stories
life sciences
national blog main
boston
national top stories
startups
third rock ventures
20/20 healthcare partners
acetylon pharmaceuticals
ally bridge group
ambys medicines
amgen ventures
amyotrophic lateral sclerosis
anthony despasqua
big data analytics
blackrock
casdin capital
cell therapy
christian angermayer
clinical trials
constellation pharmaceuticals
deals
diabetic nephropathy
dolby family ventures
enclear therapies
eventide asset management
financing
focal segmental glomerulosclerosis
funding
gene therapy
genentech
gf securities
global health sciences fund
goldfinch bio
hillel bachrach
holger willenbring
ipo
irving investors
What
diseases
3
×
new
3
×
biotech
develop
medicines
raised
aiming
ambys
analysis
associated
big
bio
bring
companies
company
control
deadly
deal
debuted
device
dialysis
disease
drug
drugs
employing
enclear
formed
future
genetic
goldfinch
harmful
ipo
kidney
later
launch
lead
liver
make
million
nets
Language
unset
Current search:
diseases
×
photo
×
new
×
" boston blog main "
×
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
EnClear Therapies Nets $10M to Test Neuro Disease ‘Dialysis’ Device
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?